Publications by authors named "J Bacharach"
The glaucoma treatment paradigm is starting to change from a more reactive approach that relies on topical medications to a more proactive approach that leverages procedural interventions. This evolution toward interventional glaucoma has been enabled by a growing array of lower-risk minimally invasive procedures such as laser trabeculoplasty, minimally invasive glaucoma surgery, and procedural pharmaceuticals. A common feature of these glaucoma interventions-as with all glaucoma interventions-is the need for early, prompt, and accurate diagnosis.
View Article and Find Full Text PDFTo compare intraocular pressure (IOP), ocular surface disease (OSD) parameters, and safety in patients with open-angle glaucoma (OAG)/ocular hypertension (OH) and concurrent OSD treated with preservative-free latanoprost 0.005% cationic emulsion (PF-latanoprost-E) or travoprost-Z 0.004% ophthalmical solution containing a soft preservative system.
View Article and Find Full Text PDFIntroduction: This study was conducted to analyze and compare the intraocular pressure (IOP) treatment effect of the slow-eluting (SE) travoprost intracameral implant to the IOP treatment effect of topical prostaglandin analog (PGA) monotherapy in a subgroup of subjects who were on pre-study PGA monotherapy prior to enrollment in the two pivotal phase 3 trials of the travoprost intracameral implant.
Methods: A combined study population of 133 subjects from two phase 3 trials, who were on topical PGA monotherapy at screening, subsequently underwent a washout period from their topical PGA, and then were randomized and administered an SE travoprost intracameral implant. The subjects were analyzed for the IOP treatment effects of the pre-study topical PGA monotherapy and the in-study SE travoprost intracameral implant.
Article Synopsis
- A clinical trial assessed the Cross-Seal vascular closure device's ability to effectively and safely achieve hemostasis in patients using large sheaths (8F-18F) for interventional procedures.
- Conducted on 147 participants, the trial showed a quick average time to hemostasis of just 0.4 minutes, with high technical success (92.3%) and a low rate of major complications (5.7%).
- Results indicate that the Cross-Seal device is a safe and effective option for patients undergoing percutaneous endovascular procedures with large-bore access.
Article Synopsis
- The study compares the sensitivity of two visual field testing algorithms, SITA-Standard and RATA-Standard, using the Radius virtual reality perimeter in adult glaucoma patients.
- It involved testing 100 patients (balanced between mild and severe glaucoma) with both algorithms and assessing differences in estimated sensitivity and concordance in glaucoma staging.
- Results show RATA-Standard has comparable sensitivity to SITA-Standard in certain ranges, with high agreement in staging severity, suggesting Radius VRP is a reliable option for glaucoma assessment.